|
- OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric cancer), cancer where the esophagus joins the stomach (gastroesophageal junction cancer), and with esophageal adenocarcinoma when your cancer cannot be removed with
- How This Treatment Works | OPDIVO® (nivolumab)
Learn how OPDIVO® (nivolumab) alone and OPDIVO® + YERVOY® (ipilimumab) in combination work with your immune system to fight cancer Ask your doctor if these immunotherapies may work for you
- Advanced PD-L1 Positive NSCLC - OPDIVO
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1
- OPDIVO with You | Patient Caregiver Support Program Registration . . .
Sign up for OPDIVO with You, a support program that offers helpful information if you are about to start or are currently on OPDIVO® (nivolumab) or an OPDIVO®-based combination Please see Indication and Important Safety Information
- Financial Information: Cost, Access Affordability - OPDIVO
Important Facts About OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) This is a summary of important information that you need to know about OPDIVO Qvantig Your healthcare team can work with you to help answer any questions you may have about this medication
- OPDIVO® Support Patient Resources | OPDIVO® (nivolumab)
Whether you're a new or continuing OPDIVO® (nivolumab) patient, find resources that can support you through a cancer diagnosis and during treatment Access helpful resources and find assistance for OPDIVO® patients here Please see Indication and Important Safety Information
- Frequently Asked Questions (FAQ) | OPDIVO® (nivolumab)
Find answers to frequently asked questions about OPDIVO® (nivolumab) including what OPDIVO® is, how immunotherapy works, and what are the side effects of OPDIVO®
- Previously Treated Advanced NSCLC | Clinical Trial Results - OPDIVO
See how OPDIVO® (nivolumab) performed in clinical trials as treatment for adults with advanced previously treated advanced non-small cell lung cancer (NSCLC) Please see Indication and Important Safety Information
|
|
|